PHILADELPHIA, Dec. 7, 2010 /PRNewswire-FirstCall/ -- ERT
(Nasdaq: ERES) a global provider of technology and services to the
pharmaceutical, biotechnology and medical device industries, today
announced the appointment of Klaus
Besier to the Company's Board of Directors. This strategic
appointment will enable ERT to draw on Mr. Besier's extensive
experience and international perspective in helping companies
develop, implement and execute global growth strategies to further
penetrate health care and clinical markets.
Mr. Besier brings to ERT more than 30 years of executive
experience in leading software technology companies. He has served
as President and CEO of SAP America, Inc. and is credited with
driving its growth in North and South
America, Australia and
New Zealand from $50 million to $1 billion in revenues in less
than five years. In addition, as President and CEO of Firepond
Inc., Mr. Besier took the company public in one of the most
successful IPOs of 2000.
Mr. Besier also held the position of President and CEO of
Neoware, Inc., where he drove significant changes in the company's
go-to-market and partner strategies. The improved corporate
structure led to significant growth and visibility for the
organization, resulting in its acquisition by HP in 2007 with a
total transaction value of more than $300
million. Most recently, Mr. Besier served as CEO of Pramata,
Inc., where he refined a go-to-market strategy that is steering the
company toward growth with Fortune 500 customers. Today, he is the
CEO of RES Software and a member of the Board of Directors of ICG
Commerce.
Joel Morganroth, Chairman and
Chief Scientific Officer of ERT, comments, "ERT strives to
continually improve in all areas of business and grow into adjacent
and complementary markets, ensuring our pledge to our customers of
'getting it done right.' With his wealth of experience and
capabilities in developing and implementing successful growth
strategies, we are confident that Klaus will greatly contribute to
the strategic direction of the business and help ERT achieve its
many goals."
Klaus Besier adds, "As the
industry leader in cardiac safety, respiratory and multi-mode ePRO
solutions for the clinical trial market, ERT has provided
unparalleled scientific and regulatory leadership to the global
health care industry. I am delighted to be part of a strong
management team consisting of individuals who share a long industry
track record. I look forward to working with them to take ERT to an
even higher level of leadership and technological innovation."
For further information on ERT and its technology and services,
please email info@ert.com, call +1 215 972 0420 or visit
www.ert.com.
About ERT
Based in Philadelphia, PA,
eResearchTechnology, Inc. (www.ert.com) is a global provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries. The Company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG)
technology and services to evaluate cardiac safety in clinical
development. It is also a leading provider of centralized
respiratory technology and services to evaluate pulmonary function
efficacy and safety in clinical development. Sponsors can
further use the Company's solutions to streamline the clinical
trials process by automating the collection, analysis, and
distribution of ePRO clinical data using multi-mode technology in
all phases of clinical development as well as selected medical
devices for the clinical trials and healthcare industries.
Statements included in this release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve a
number of risks and uncertainties, which could cause actual results
to differ materially from those expressed or implied from such
statements. These risks and uncertainties include, without
limitation, the Company's ability to obtain new contracts,
variability in size, scope, and duration of projects, integration
of acquisitions, competitive factors, technological development,
market demand, and other factors described in the Company's filings
with the Securities and Exchange Commission. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
SOURCE ERT